PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-27.41%
Both companies show declining cash positions (-27.41% vs CRVO's -33.25%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-27.41%
Cash + STI yoy 0.75-0.9x CRVO's -33.25%. Bill Ackman would wonder if competitor is building liquidity more aggressively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.07%
Higher Other Current Assets Growth compared to CRVO's zero value, indicating worse performance.
-28.37%
Similar yoy growth to CRVO's -28.39%. Walter Schloss notes comparable short-term expansions. Investigate quality of these assets.
1187.39%
≥ 1.5x CRVO's 84.24%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.01%
Less than half of CRVO's 7.12%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
252.00%
≥ 1.5x CRVO's 3.41%. David Dodd sees significantly higher long-term asset buildup. Confirm synergy with strategy.
No Data
No Data available this quarter, please select a different quarter.
-17.83%
1.25-1.5x CRVO's -12.16%. Bruce Berkowitz sees a stronger asset build. Check if it's producing returns.
-8.53%
Less than half of CRVO's 141.43%. David Dodd sees a more disciplined AP approach or lower volume.
-29.62%
Higher Short-Term Debt Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
12.29%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-3.44%
Less than half of CRVO's 48.43%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7668.72%
Above 1.5x CRVO's 2.97%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
13.42%
Similar yoy to CRVO's 17.08%. Walter Schloss sees parallel expansions in total liabilities.
2.97%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-3.03%
0.75-0.9x CRVO's -3.44%. Bill Ackman questions if competitor reinvests profits more robustly.
25.83%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-39.38%
≥ 1.5x CRVO's -17.02%. David Dodd sees stronger capital base growth than competitor.
-17.83%
1.25-1.5x CRVO's -12.16%. Bruce Berkowitz checks if expansions are well-justified by ROI.
No Data
No Data available this quarter, please select a different quarter.
499.58%
Higher Total Debt Growth compared to CRVO's zero value, indicating worse performance.
37.73%
Similar yoy changes to CRVO's 37.18%. Walter Schloss sees parallel net leverage strategies.